0 Items
Select Page

Legionella

The bacterium L. pneumophila was first identified in 1977, as the cause of an outbreak of severe pneumonia in a convention centre in the USA in 1976. It has since been associated with outbreaks linked to poorly maintained artificial water systems, particularly cooling towers or evaporative condensers associated with air conditioning and industrial cooling, hot and cold water systems in public and private buildings, and whirlpool spas.

 

Our monoclonal antibodies can be used in support of assay development and R&D into Legionella infection.

Legionella background

L. pneumophila is an opportunistic intracellular pathogen that was first recognised in a group of individuals, presenting with a lung infection, who had attended a convention in Philadelphia in 1976. It is the causative agent of a severe type of pneumonia referred to as Legionnaires’ disease. The symptoms of Legionnaires’ disease include shortness of breath, cough, headache, fever and muscle ache, which can occur 2 – 10 days after exposure. Complications associated with infection may result in death. L. pneumophila may also cause a mild form of disease known as Pontiac fever, which is self-limiting and doesn’t require hospitalisation (CDC). Both forms of the disease may also be referred to as Legionellosis.

Legionella Antibodies

We offer a pair of monoclonal antibodies specific for Legionella detection, suitable for use in immunoassay development.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Why Zika virus’s cross-reactivity with Dengue might be hampering your research

Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the...

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

8 + 15 =

Live Customer Feedback